News

Takeda Vaccine Business Division executive vice president Rajeev Venkayya said Takeda’s acquisition of LigoCyte will expand its vaccine business. The acquisition will help Takeda gain Norovirus vaccine candidate

As part of the contract, JBI will use Wolters Health’s Ovid platform, as a complete channel for EBP solution on its OvidSP and Nursing@Ovid research platforms. Through the

David Cobrinik and his colleagues at the Memorial Sloan-Kettering Cancer Center will carry on the clinical studies. The $300,000 grant spread over six months will be used to

The MDCO-2010 was being developed as an intravenous antifibrinolytic drug for the reduction of blood loss during surgery. Although the cause of the safety issues and any potential

L-carnitine, which plays a vital role in fat and energy metabolism, is a nutrient produced in the body and found in some dietary sources and shuttles long-chain fatty

The company previously signed an agreement with the University of Medicine & Dentistry of New Jersey to conduct the clinical trial of the UMK-121 drug therapy on patients

Xilonix blocks an inflammatory substance (IL-1a) produced by the body in response to tumor growth, which plays a role in cancer progression and the development of lethal symptoms

The data assessing immunogenicity, tolerability and safety of Prevenar 13 support EU regulatory filing and planned worldwide regulatory filings for the age group. Pfizer vaccine clinical research and

The CYSTARAN 0.44% solution, which is developed in collaboration with the National Institutes of Health (NIH), is designated as an orphan drug in the US. The FDA approval